New app helps family doctors care for adults with disabilities

U of A specialist identified gaps in care as patients age, developed app on his own time to ‘make a difference’

New app helps family doctors care for adults with disabilitiesA University of Alberta family doctor has developed an app that he hopes will improve medical care for adults with intellectual and developmental disabilities. Kyle Sue, clinical assistant professor of developmental pediatrics in the Faculty of Medicine & Dentistry, built the app with the help of a friend to present family physicians with the best treatment…

Twenty per cent hike in flu vaccinations ambitious but attainable

U of A professor says COVID-19 crisis has provided much-needed public education in how vaccines can prevent deadly viruses

Twenty per cent hike in flu vaccinations ambitious but attainableA pharmacy researcher predicts more of us will roll up our sleeves for the influenza vaccine this fall thanks to the crash course we’ve all had recently on viruses and how to prevent them. “Because of COVID-19, people are becoming a lot more aware of how susceptible they are to viruses and virus-caused infections, especially…

Project aims to make water treatment greener, more efficient

U of A computing scientists working with Edmonton company to find out if applying AI to water treatment is a financial, environmental win-win

Project aims to make water treatment greener, more efficientA pilot project leveraging the University of Alberta’s artificial intelligence expertise to improve the process of making drinking water safe is up and running in Drayton Valley, Alta. The U of A’s Reinforcement Learning and Artificial Intelligence Lab, along with the Alberta Machine Intelligence Institute, an Alberta not-for-profit institute with U of A affiliations, Edmonton infrastructure technology…

Wearable tech helps people manage multiple sclerosis

Wearable tech helps people manage multiple sclerosisUniversity of Alberta researchers are teaming up with a precision-health innovator to develop a low-cost wearable sensor to help people suffering from chronic neurologic conditions treat their illness remotely, while reducing the frequency and costs of hospital visits. Hossein Rouhani, an assistant professor in the Faculty of Engineering and primary investigator in the Neuromuscular Control and Biomechanics Laboratory,…

Salt-coated masks can kill COVID-19

Salt-coated masks can kill COVID-19In 2017, Hyo-Jick Choi and his engineering research team released a study outlining a breathable surgical mask that just doesn’t catch pathogens from entering the respiratory system; it kills them. Choi, a professor in the Faculty of Engineering who runs the Sustainable Engineering and Drug Delivery Design (SEƎD) lab, developed the idea of an antiviral, antibacterial filter for a…

New drug to treat muscular dystrophy based on U of A research

Created using synthetic DNA, viltolarsen is an excellent example of precision medicine

New drug to treat muscular dystrophy based on U of A researchA University of Alberta researcher’s past work has led to a new drug being approved for use in the United States to treat patients suffering from Duchenne muscular dystrophy (DMD). The drug, viltolarsen, was approved for use in Japan earlier this year and passed a significant hurdle in August when the U.S. Food and Drug…

Paleontologists identify new species of mosasaur

Paleontologists identify new species of mosasaurA new species of an ancient marine reptile evolved to strike terror into the hearts of the normally safe, fast-swimming fish has been identified by a team of University of Alberta researchers. The discovery sheds light on what it took to survive in highly competitive ecosystems. Gavialimimus almaghribensis, a new type of mosasaur, was catalogued and…

Type 2 diabetes drug buys time for a failing heart: study

The diabetes drug increased ketone levels, which might be the key to improving cardiac metabolism

Type 2 diabetes drug buys time for a failing heart: studyIn 2015, researchers began noticing that a drug used to treat Type 2 diabetes, empagliflozin, came with the added benefit of decreasing hospitalization for heart failure and death from cardiovascular causes in those patients. “It was very unexpected, because this drug is targeted and marketed for Type 2 diabetes, not heart failure,” said Kim Ho,…
1 2 3 11